Cinacalcet — Discount Pricing
Cinacalcet is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Cinacalcet Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $89.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Cinacalcet
Cinacalcet is a prescription medication. Ask your doctor if Cinacalcet is right for you.
How to Check Cinacalcet Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Cinacalcet at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Diabetes & Metabolism
What Cinacalcet is approved for (FDA label)
Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Limitations of Use: Cinacalcet is not indicated for use in patients with CKD who are not on dialysis Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in adult patients with primary HPT who are unable to parathyroidectomy. ( 1.3 ) 1.1 Secondary Hyperparathyroidism Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis [see Clinical Studies (14.1) ]. Limitations of Use: Cinacalcet tablets are not indicated for use in patients with CKD who are not on dialysis because of an increased risk of hypocalcemia [see Warnings and Precautions (5.1) ] 1.2 Parathyroid Carcinoma Cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma [see Clinical Studies (14.2) ]. 1.3 Primary Hyperparathyroidism Cinacalcet tablets are indicated for the treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy [see Clinical Studies (14.3) ].
Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Cinacalcet (FDA label)
Cinacalcet tablets are available as film-coated tablets. Cinacalcet tablets are formulated as light-green, film coated, oval-shaped tablets marked with "SCT" on one side and "30" or "60" or "90" on the opposite side of the 30 mg, 60 mg, or 90 mg strengths, respectively. Tablets: 30 mg,60 mg, and 90 mg tablets ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 44b548ef-1679-4d15-86ad-0d9636b48a45. SPL document ID: 5a1d2f2c-e925-4e9e-e063-6394a90a93b1. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Cinacalcet (FDA label)
The following adverse reactions are discussed in greater detail in other sections of labeling: Hypocalcemia [see Warnings and Precautions (5.1) ] Upper Gastrointestinal Bleeding [see Warnings and Precautions (5.2) ] Hypotension, Worsening Heart Failure and/or Arrhythmias [see Warnings and Precautions (5.3) ] Adynamic Bone Disease [see Warnings and Precautions (5.4) ] The most common adverse reactions (i.e., ≥ 25%) associated with cinacalcet were nausea and vomiting. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Strides Pharma Inc. at 1-877-244-9825 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Source: FDA prescribing information (DailyMed). Set ID: 44b548ef-1679-4d15-86ad-0d9636b48a45. SPL document ID: 5a1d2f2c-e925-4e9e-e063-6394a90a93b1. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Cinacalcet (FDA label)
Cinacalcet tablets treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see Warnings and Precautions (5.1) ]. Cinacalcet tablets treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range. ( 4 , 5.1 )
Source: FDA prescribing information (DailyMed). Set ID: 44b548ef-1679-4d15-86ad-0d9636b48a45. SPL document ID: 5a1d2f2c-e925-4e9e-e063-6394a90a93b1. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Cinacalcet (FDA label)
Hypocalcemia: Life threatening events and fatal outcomes were reported. Hypocalcemia can prolong QT interval, lower the threshold for seizures, and cause hypotension, worsening heart failure, and/or arrhythmia. Monitor serum calcium carefully for the occurrence of hypocalcemia during treatment ( 2.4 , 5.1 ) Upper Gastrointestinal (GI) Bleeding: Patients with risk factors for upper GI bleeding may be at increased risk.
Source: FDA prescribing information (DailyMed). Set ID: 44b548ef-1679-4d15-86ad-0d9636b48a45. SPL document ID: 5a1d2f2c-e925-4e9e-e063-6394a90a93b1. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Cinacalcet (FDA label)
Co-administration with a strong CYP3A4 inhibitor may increase serum levels of cinacalcet. Dose adjustment and monitoring of iPTH serum phosphorous and serum calcium may be required. ( 7.1 ) Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6. ( 7.2 ) 7.1 Strong CYP3A4 Inhibitors Cinacalcet is partially metabolized by CYP3A4. Dose adjustment of cinacalcet tablets may be required if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole).
Source: FDA prescribing information (DailyMed). Set ID: 44b548ef-1679-4d15-86ad-0d9636b48a45. SPL document ID: 5a1d2f2c-e925-4e9e-e063-6394a90a93b1. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.